IXICO

IXICO operates in the specialist end of clinical research services: it combines neuroimaging operations, quantitative biomarker analysis, and trial support for central nervous system studies. Its stated coverage includes Alzheimer’s, Parkinson’s, Huntington’s, multiple sclerosis, and rare neurological disorders. The IXICO Platform and TrialTracker are positioned to manage imaging data and analysis, while associated services span imaging-site coordination, multimodal MRI and PET analysis, and post-marketing surveillance. IXICO reports an international network of more than 2,000 imaging centres and experience across hundreds of trials and hundreds of thousands of scans, which indicate operational scale in its niche. The comparable-company information available does not identify distinct peers, so naming specific competitors or ranking IXICO against them would not be reliable. Its public listing as LSE:IXI and its October 2024 post-IPO raise also distinguish it from a typical venture-backed early-stage clinical technology company.

IXICO’s trajectory reflects a transition from an established neuroscience imaging specialist to a publicly listed provider investing in commercial expansion. Founded in 2004, it went public in October 2013 and has since recorded seven funding rounds, including post-IPO equity raises in 2018 and October 2024. The company’s reported aggregate funding is $17.84 million; the latest raise was £4 million, or about $5.23 million, with Gresham House leading. More recently, the July 2026 revenue-forecast lift following contract wins and a wider client base provides the strongest stated indication of accelerating demand. Bram Goorden’s appointment as CEO in August 2024 marked a leadership inflection point ahead of this commercial emphasis. The next trajectory assessment therefore depends on whether contract wins translate into sustained revenue growth.